UNICA IRIS Institutional Research Information System

SCARTOZZI, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 250.033
NA - Nord America 24.601
AS - Asia 10.764
SA - Sud America 1.997
AF - Africa 215
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 19
Totale 287.665
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 243.632
US - Stati Uniti d'America 24.202
SG - Singapore 4.759
CN - Cina 3.860
UA - Ucraina 1.739
BR - Brasile 1.643
SE - Svezia 1.360
DE - Germania 1.056
VN - Vietnam 624
FI - Finlandia 622
GB - Regno Unito 595
KR - Corea 297
FR - Francia 267
TR - Turchia 245
CA - Canada 233
IN - India 201
HK - Hong Kong 166
NL - Olanda 148
AR - Argentina 135
MX - Messico 108
AT - Austria 101
JP - Giappone 98
PL - Polonia 94
RU - Federazione Russa 88
BD - Bangladesh 85
ZA - Sudafrica 74
IQ - Iraq 69
ES - Italia 61
BE - Belgio 55
EC - Ecuador 54
ID - Indonesia 53
IR - Iran 46
IE - Irlanda 43
MA - Marocco 41
PK - Pakistan 38
CO - Colombia 35
VE - Venezuela 33
AU - Australia 30
UZ - Uzbekistan 28
AE - Emirati Arabi Uniti 26
SA - Arabia Saudita 23
CL - Cile 22
PE - Perù 21
LT - Lituania 20
PY - Paraguay 20
JO - Giordania 19
EU - Europa 18
UY - Uruguay 18
EG - Egitto 17
KE - Kenya 14
PH - Filippine 14
CH - Svizzera 13
HR - Croazia 13
IL - Israele 13
PT - Portogallo 13
RO - Romania 13
AL - Albania 12
CZ - Repubblica Ceca 12
DZ - Algeria 12
TW - Taiwan 12
BO - Bolivia 11
MY - Malesia 11
TN - Tunisia 11
DO - Repubblica Dominicana 10
JM - Giamaica 9
NP - Nepal 9
PA - Panama 9
AM - Armenia 8
AZ - Azerbaigian 8
BG - Bulgaria 8
CI - Costa d'Avorio 8
DK - Danimarca 8
IS - Islanda 8
SK - Slovacchia (Repubblica Slovacca) 8
TH - Thailandia 8
GR - Grecia 7
NO - Norvegia 7
TT - Trinidad e Tobago 7
ET - Etiopia 6
HN - Honduras 6
JE - Jersey 6
KG - Kirghizistan 6
LV - Lettonia 6
TZ - Tanzania 6
BY - Bielorussia 5
LK - Sri Lanka 5
NG - Nigeria 5
BZ - Belize 4
GE - Georgia 4
GY - Guiana 4
KZ - Kazakistan 4
MU - Mauritius 4
NZ - Nuova Zelanda 4
OM - Oman 4
RS - Serbia 4
AO - Angola 3
BB - Barbados 3
BH - Bahrain 3
BJ - Benin 3
CR - Costa Rica 3
Totale 287.616
Salva come PNG Salva come JPEG
Città #
Cagliari 233.658
Uta 8.475
Fairfield 2.638
Ashburn 2.143
Singapore 2.116
Dallas 2.052
Woodbridge 1.936
Chandler 1.562
Boardman 1.433
Houston 1.369
Seattle 1.040
Wilmington 1.005
Cambridge 903
Jacksonville 890
Ann Arbor 830
Nyköping 830
Beijing 699
Los Angeles 489
Hefei 463
Dearborn 391
Nanjing 318
Helsinki 289
Seoul 274
New York 250
Buffalo 237
Santa Clara 225
Boston 222
The Dalles 201
Ho Chi Minh City 180
Shanghai 173
Istanbul 168
Dong Ket 166
Hong Kong 154
San Diego 149
Guangzhou 138
São Paulo 136
Milan 135
Chicago 127
Rome 115
Shenyang 109
Munich 107
Redondo Beach 96
Toronto 96
Krefeld 95
Tianjin 93
Nanchang 90
Hanoi 89
Hebei 85
Nuremberg 85
London 84
Verona 82
Frankfurt am Main 80
Jiaxing 79
Montreal 71
Changsha 70
Amsterdam 69
Warsaw 67
Council Bluffs 65
Rio de Janeiro 65
Tokyo 61
Phoenix 55
Norwalk 51
Zhengzhou 51
Brussels 50
Pune 50
Stockholm 50
Bad Bellingen 49
Vienna 48
Mountain View 47
Atlanta 46
Brooklyn 46
Sassari 46
Washington 46
Chennai 44
Columbus 44
Johannesburg 43
Jinan 42
Orange 41
Florence 40
Redwood City 40
Belo Horizonte 38
Turku 37
Lappeenranta 36
Ankara 35
Mexico City 35
Wuhan 35
Dublin 34
San Francisco 34
Düsseldorf 32
Manchester 31
Poplar 31
Salt Lake City 31
Denver 30
Shenzhen 29
Hangzhou 28
Ningbo 27
Baghdad 26
Casablanca 26
Tashkent 26
Kunming 25
Totale 271.872
Salva come PNG Salva come JPEG
Nome #
Thyroid dysfunction and ultrasonography features in patients with metastatic colorectal cancer treated with Regorafenib: preliminary results from a single prospective cohort study. 4.839
Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy 4.143
Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy 3.549
Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer 3.347
Clustered protocadherins methylation alterations in cancer 3.278
BRAF-mutant colorectal cancer, a different breed evolving 3.212
The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy 3.143
Systemic therapy for the treatment of endometrial cancer 3.066
Aspirin and cancer risk 3.065
null 3.029
Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link? 2.942
Thyroid dysfunction and ultrasonography features in patients with metastatic colorectal cancer treated with Regorafenib. Results from a single centre prospective cohort study. 2.914
Molecular-biology-driven treatment for metastatic colorectal cancer 2.718
Breast MRI: Clinical Indications, Recommendations, and Future Applications in Breast Cancer Diagnosis 2.642
HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples 2.640
Acetylsalicylic acid as a neo-adjuvant agent during preoperative chemoradiation for rectal cancer 2.635
Thyroid dysfunction in disguise and treatment-related fatigue in the spotlight among metastatic colorectal cancer patients receiving regorafenib: Implications for clinical management. 2.589
CREAM study: Clinical correlation between ipilimumab-Related colitis And intestinal Microbiote in metastatic melanoma patients 2.545
Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report 2.457
Alterazioni tiroidee funzionali e morfologiche in pazienti affetti da carcinoma del colon-retto metastatico in trattamento con Regorafenib. Risultati di uno studio prospettico. 2.406
Colorectal cancer early detection in stool samples tracing CPG islands methylation alterations affecting gene expression 2.327
Alterazioni tiroidee funzionali e morfologiche in pazienti affetti da carcinoma del colon-retto metastatico in trattamento con Regorafenib. 2.304
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 2.301
Gold nanoparticles: A new golden Era in oncology? 2.234
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? 2.218
HYPOTHYROIDISM AND THYROID AUTOIMMUNITY AS A PROGNOSTIC BIOMARKER OF BETTER RESPONSE IN METASTATIC CANCER LONG SURVIVORS TREATED WITH SUNITINIB 2.209
Health related quality of life in patients with onco-hematological diseases 2.191
Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going? 2.177
Immunotherapy associated pulmonary toxicity: Biology behind clinical and radiological features 2.132
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 2.122
The abscopal effect in the era of cancer immunotherapy: a spontaneous synergism boosting anti-tumor immunity? 2.114
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 2.098
Ipotiroidismo e autoimmunità tiroidea in pazienti affetti da carcinoma renale metastatico trattati con sunitinib con un follow-up di 30 mesi. 2.082
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 2.009
Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: Key role of interleukin-6 1.996
The immune revolution in gastrointestinal tumours: leading the way or just following? 1.947
Hypothyroidism and thyroid autoimmunity in metastatic renal cell carcinoma patients treated with sunitinib: 2 years follow-up of long survivors from a single centre experience. 1.937
From central to sentral (Serum angiogenesis central): Circulating predictive biomarkers to anti-VEGFR therapy 1.892
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study 1.827
Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer 1.745
Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy 1.653
The Quality of Life of People with Solid Cancer is Less Worse than Other Diseases with better Prognosis, Except in the Presence of Depression 1.611
New therapeutic targets in pancreatic cancer 1.593
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 1.585
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 1.576
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 1.544
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients? 1.491
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: Training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 1.474
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 1.433
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib 1.393
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications 1.388
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy 1.373
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 1.354
The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors 1.329
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment 1.308
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 1.302
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 1.264
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 1.263
Immunotherapy for colorectal cancer: where are we heading? 1.249
Cancer immunotherapy-associated hypophysitis 1.232
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 1.211
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 1.195
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? 1.192
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis 1.186
Molecular-driven treatment for biliary tract cancer: the promising turning point 1.184
The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials 1.179
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced hcc patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group 1.165
The role of fetal programming in human carcinogenesis - May the Barker hypothesis explain interindividual variability in susceptibility to cancer insurgence and progression? 1.150
How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world 1.137
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 1.115
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma 1.107
null 1.080
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? 1.077
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An Innovate study protocol 1.051
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 1.025
Lactate dehydrogenase in hepatocellular carcinoma: something old, something new 1.015
Colorectal cancer promoter methylation alteration affects the expression of glutamate ionotropic receptor AMPA type subunit 4 alternative isoforms potentially relevant in colon tissue 1.009
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors 1.006
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 996
The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study 987
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 983
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 958
Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients 946
Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer 946
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 945
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 942
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 938
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib 936
FOLFOX or CAPOX in stage II to III colon cancer: Efficacy results of the italian three or six colon adjuvant trial 921
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma 920
STUDY OF VALIDATION OF ANGIOGENESIS POLYMORPHISMS IN HCC PATIENTS TREATEDWITH SORAFENIB. INNOVATE STUDY 918
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab 910
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 905
Balance between the stem cell marker CD44 and CDX2 expression in colorectal cancer 903
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? 901
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib 865
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 862
A Multidisciplinary Approach to Patients with Psoriasis and a History of Malignancies or On-Treatment for Solid Tumors: A Narrative Literature Review 834
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma 834
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment 816
Totale 171.686
Salva come PNG Salva come JPEG
Categoria #
all - tutte 447.843
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 447.843
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202123.492 0 0 0 0 0 6.963 3.642 3.554 1.399 3.262 2.661 2.011
2021/202217.497 1.352 1.105 469 843 911 960 717 3.198 1.945 1.597 2.150 2.250
2022/202328.830 3.008 3.934 3.119 2.545 2.382 2.998 1.411 2.068 2.109 1.809 2.167 1.280
2023/202433.122 1.257 1.347 1.666 2.049 2.733 4.826 4.990 4.292 1.998 1.969 2.911 3.084
2024/202564.485 13.438 14.638 7.457 7.684 3.957 4.662 7.252 599 1.298 1.130 988 1.382
2025/202613.455 1.787 1.213 3.746 2.708 2.032 1.969 0 0 0 0 0 0
Totale 289.328